Studies have shown that RRAGC-activating mutations are found in approximately 10% of follicular lymphomas, with the mutated RRAGC protein showing increased binding to RPTOR (raptor) and significantly reduced interaction with the product of the tumor suppressor gene FLCN (follicle protein). This evidence concerns the gene RPTOR and follicular lymphoma.